查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2007858

基因編輯技術市場預測至2034年—按類型、組件、交付方式、應用、最終用戶和地區分類的全球分析

Gene Editing Technologies Market Forecasts to 2034 - Global Analysis By Type, Component, Delivery Method, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，預計到 2026 年，全球基因編輯技術市場規模將達到 68 億美元，並在預測期內以 17.2% 的複合年成長率成長，到 2034 年將達到 234 億美元。

基因編輯技術是指一系列分子生物學工具，它們能夠透過在預定的基因組位點引入位點特異性的切割、缺失、插入或鹼基水平的改變，對活細胞和生物體中的DNA序列進行精確且靶向的修飾。這些技術包括CRISPR-Cas核酸酶系統、活化因子樣效應核酸酶、鋅指核酸酶、Meganucleases、鹼基編輯和先導編輯平台。透過病毒載體、脂質奈米顆粒或電穿孔等方式遞送，這些技術可應用於基因治療、功能基因體學、農業生物技術、藥物研發和細胞株工程等領域。

CRISPR療法研發管線的拓展

CRISPR治療產品線的擴展是市場成長的驅動力，鐮狀細胞貧血症和BETA地中海貧血療法的突破性臨床核准已在商業性證明了基因編輯技術作為一種根治性治療方法的潛力。多個涵蓋腫瘤、罕見遺傳疾病和感染疾病適應症的後期臨床項目正在增強投資者和製藥合作夥伴對商業化前景的信心。監管機構正在製定針對基因編輯的指導框架，以降低核准的不確定性，這正在加速對該產品線的投資，並擴大包括鹼基編輯和先導編輯在內的下一代編輯平台的治療目標市場。

關於非目標編輯的安全問題

脫靶編輯帶來的安全隱患仍然是臨床和監管方面持續存在的障礙。脫靶位點的非預期基因組修飾具有致癌性或致病風險，必須在獲得監管部門核准前進行全面闡明。包括FDA在內的監管機構要求使用全基因組定序進行廣泛的脫靶分析，這給臨床前開發帶來了沉重的成本負擔。早期基因編輯臨床計畫中的不利事件會加劇監管審查，延長臨床試驗暫停後的審查期，增加開發風險溢價，並限制對新型編輯平台的商業性投資。

農業生物技術應用

隨著美國、日本和阿根廷的監管機構將基因編輯作物與傳統基因改造生物區分開來，並簡化產品核可流程，基因編輯技術在農業生物技術領域的應用展現出巨大且快速成長的商業性機會。精準的基因編輯技術無需引入外源DNA，即可培育出抗病性、抗旱性、營養價值更高、保存期限更長的作物。日益成長的糧食安全問題和應對氣候變遷的迫切需求，正迫使農業相關企業加快對基因編輯研究的投資，其商業用戶群也正從生物醫學領域擴展到更廣泛的範圍。

倫理和監管方面的暫停風險

圍繞著人類生殖細胞基因編輯的倫理爭議以及監管機構可能採取的暫停措施，對市場發展的信心構成系統性威脅。在發生多起備受矚目的未經授權的基因改造案例後，這種趨勢尤其明顯。國際監管機構和生物倫理委員會仍在就人類基因編輯的可接受界限展開辯論，由此產生的政策不確定性使長期產業計畫變得複雜。關鍵市場的限制性立法可能導致研發禁令，這不僅會限制目標市場的範圍，還可能為參與應用這些爭議性編輯技術的公司帶來聲譽風險。

新冠疫情的影響：

新冠疫情加速了人們對基因編輯技術的認知和投資，並透過CRISPR基因編輯技術快速病毒檢測診斷試劑盒的緊急監管核准，展現了其在治療應用之外的多功能性。疫情期間對核酸遞送技術（包括脂質奈米顆粒）的投資，直接推動了基因編輯療法遞送基礎設施的完善。疫情後，支付方和臨床醫師對基因組醫學的認知不斷提高，促使基因編輯療法的報銷範圍持續擴大。

在預測期內，基礎編輯技術細分市場預計將佔據最大的市場佔有率。

預計在預測期內，鹼基編輯技術將佔據最大的市場佔有率，因為它能夠進行精確的單核苷酸替換，而不會造成雙鏈DNA斷裂，從而顯著降低了與傳統CRISPR-Cas核酸酶系統相關的脫靶編輯和染色體重排風險。這種卓越的安全性正在加速監管部門的核准和針對點突變引起的遺傳疾病的治療應用的臨床部署。多個鹼基編輯專案正在進行臨床試驗，形成了一個強大的後期開發平臺，推動該領域在銷售方面保持主導地位。

預計試劑和耗材領域在預測期內將呈現最高的複合年成長率。

在預測期內，試劑和耗材領域預計將呈現最高的成長率，這主要得益於基因編輯工作流程在研究和臨床檢查室中的日益普及，從而持續推動對嚮導RNA組分、Cas蛋白試劑、檢驗載體試劑盒和驗證檢測耗材的需求。學術界和製藥業在基因編輯應用整體的研究活動活性化，也帶動了耗材採購量的共同成長。各機構間基因編輯研究通訊協定的日益標準化提高了耗材的可替代性，使主要試劑供應商能夠從批量採購合約和規模化分銷中獲益。

市佔率最大的地區：

在整個預測期內，北美預計將保持最大的市場佔有率，這得益於主導地位、基因編輯生物技術公司的集中度，以及美國國立衛生研究院（NIH）和私人企業對基礎和轉化基因編輯研究的大力資助。美國擁有全球大部分處於臨床階段的基因編輯計畫。美國食品藥物管理局（FDA）針對細胞和基因治療產品所製定的完善法規結構，以及有利的智慧財產權保護體系，鞏固了北美在基因編輯商業化領域的主導地位。

複合年成長率最高的地區：

在預測期內，亞太地區預計將呈現最高的複合年成長率，這主要得益於中國、韓國和日本基因組研究投資的快速成長、政府主導的國家基因編輯研究項目以及國內生物技術產業能力的提升。中國在CRISPR研究論文和臨床應用方面取得了顯著進展，政府資金大力支持國家基因組創新策略。全部區域學術和醫藥研究基礎設施的擴展，正在推動對基因編輯研究工具、試劑和治療藥物開發服務的需求成長。

免費客製化服務：

所有購買此報告的客戶均可享受以下免費自訂選項之一：

  • 企業概況
    • 對其他市場參與者（最多 3 家公司）進行全面分析
    • 對主要企業進行SWOT分析（最多3家公司）
  • 區域細分
    • 應客戶要求，我們提供主要國家和地區的市場估算和預測，以及複合年成長率（註：需進行可行性檢查）。
  • 競爭性標竿分析
    • 根據產品系列、地理覆蓋範圍和策略聯盟對主要企業進行基準分析。

目錄

第1章：執行摘要

  • 市場概覽及主要亮點
  • 促進因素、挑戰與機遇
  • 競爭格局概述
  • 戰略洞察與建議

第2章：研究框架

  • 研究目標和範圍
  • 相關人員分析
  • 研究假設和限制
  • 調查方法

第3章 市場動態與趨勢分析

  • 市場定義與結構
  • 主要市場促進因素
  • 市場限制與挑戰
  • 投資成長機會和重點領域
  • 產業威脅與風險評估
  • 技術與創新展望
  • 新興市場/高成長市場
  • 監管和政策環境
  • 新冠疫情的影響及復甦前景

第4章：競爭環境與策略評估

  • 波特五力分析
    • 供應商的議價能力
    • 買方的議價能力
    • 替代品的威脅
    • 新進入者的威脅
    • 競爭公司之間的競爭
  • 主要企業市佔率分析
  • 產品基準評效和效能比較

第5章：全球基因編輯技術市場：按類型分類

  • CRISPR-Cas系統
  • TALEN（轉錄活化因子樣效應核酸酶）
  • 鋅指核酸酶（ZFN）
  • Meganucleases
  • 基礎編輯技術
  • 進階編輯技術
  • 其他技術類型

第6章 全球基因編輯技術市場：依組件分類

  • 試劑和耗材
  • 裝置
  • 軟體和生物資訊學工具
  • 服務
  • 成套工具
  • 酵素
  • 其他規則

第7章 全球基因編輯技術市場：以交付方式分類

  • 病毒載體
  • 非病毒載體
  • 電穿孔
  • 顯微注射
  • 脂質奈米顆粒
  • 實體交付方式
  • 其他配送方式

第8章 全球基因編輯技術市場：依應用領域分類

  • 基因治療
  • 農業生物技術
  • 藥物發現與開發
  • 功能基因體學
  • 細胞株工程
  • 診斷發展
  • 其他用途

第9章 全球基因編輯技術市場：依最終用戶分類

  • 生技公司
  • 製藥公司
  • 學術研究機構
  • 受託研究機構（CRO）
  • 農業相關企業
  • 臨床研究中心
  • 其他最終用戶

第10章 全球基因編輯技術市場：依地區分類

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 比利時
    • 瑞典
    • 瑞士
    • 波蘭
    • 其他歐洲國家
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 泰國
    • 馬來西亞
    • 新加坡
    • 越南
    • 其他亞太國家
  • 南美洲
    • 巴西
    • 阿根廷
    • 哥倫比亞
    • 智利
    • 秘魯
    • 其他南美國家
  • 世界其他地區（RoW）
    • 中東
      • 沙烏地阿拉伯
      • 阿拉伯聯合大公國
      • 卡達
      • 以色列
      • 其他中東國家
    • 非洲
      • 南非
      • 埃及
      • 摩洛哥
      • 其他非洲國家

第11章 策略市場資訊

  • 工業價值網路和供應鏈評估
  • 空白區域和機會地圖
  • 產品演進與市場生命週期分析
  • 通路、經銷商和打入市場策略的評估

第12章 產業趨勢與策略舉措

  • 併購
  • 夥伴關係、聯盟和合資企業
  • 新產品發布和認證
  • 擴大生產能力和投資
  • 其他策略舉措

第13章：公司簡介

  • CRISPR Therapeutics AG
  • Editas Medicine
  • Intellia Therapeutics
  • Sangamo Therapeutics
  • Caribou Biosciences
  • Beam Therapeutics
  • Precision BioSciences
  • Horizon Discovery Group plc
  • Lonza Group AG
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • Agilent Technologies, Inc.
  • Danaher Corporation
  • GenScript Biotech Corporation
  • Integrated DNA Technologies（IDT）
  • Takara Bio Inc.
  • New England Biolabs
  • Bluebird Bio, Inc.
Product Code: SMRC34762

According to Stratistics MRC, the Global Gene Editing Technologies Market is accounted for $6.8 billion in 2026 and is expected to reach $23.4 billion by 2034 growing at a CAGR of 17.2% during the forecast period. Gene editing technologies refer to a suite of molecular biology tools that enable precise, targeted modification of DNA sequences within living cells and organisms by introducing site-specific cuts, deletions, insertions, or base-level alterations at predetermined genomic loci. They include CRISPR-Cas nuclease systems, transcription activator-like effector nucleases, zinc finger nucleases, meganucleases, base editing, and prime editing platforms. Delivered via viral vectors, lipid nanoparticles, or electroporation, these technologies serve gene therapy, functional genomics, agricultural biotechnology, drug discovery, and cell line engineering applications.

Market Dynamics:

Driver:

CRISPR Therapeutic Pipeline Growth

CRISPR therapeutic pipeline growth is the primary market driver as landmark clinical approvals for sickle cell disease and beta-thalassemia treatments have commercially validated gene editing technology as a curative intervention modality. Multiple late-stage clinical programs across oncology, rare genetic diseases, and infectious disease indications are generating investor and pharmaceutical partner confidence in the commercial pathway. Regulatory agencies are developing gene editing-specific guidance frameworks that reduce approval uncertainty, accelerating pipeline investment and broadening the therapeutic addressable market for next-generation editing platforms including base and prime editing.

Restraint:

Off-target Editing Safety Concerns

Off-target editing safety concerns represent a persistent clinical and regulatory barrier as unintended genomic modifications at non-target loci carry carcinogenic or pathological risk that must be comprehensively characterized before regulatory approval. Regulators including the FDA require extensive off-target analysis using whole-genome sequencing, creating significant preclinical development cost burdens. Adverse events in early gene editing clinical programs have heightened regulatory scrutiny and extended clinical hold review timelines, increasing development risk premiums and constraining commercial investment in novel editing modality platforms.

Opportunity:

Agricultural Biotechnology Applications

Agricultural biotechnology applications represent a large and growing commercial opportunity for gene editing technologies as regulatory agencies in the United States, Japan, and Argentina distinguish gene-edited crops from traditional genetically modified organisms, streamlining product approval pathways. Precision gene editing enables development of crops with enhanced disease resistance, drought tolerance, improved nutritional profiles, and extended shelf lives without introducing foreign DNA. Growing food security concerns and climate change adaptation demands are compelling agricultural companies to accelerate gene editing research investment, expanding the commercial user base beyond biomedical applications.

Threat:

Ethical and Regulatory Moratoria Risks

Ethical controversies and potential regulatory moratoria on human germline gene editing represent systemic threats to market development confidence, particularly following high-profile incidents involving non-consented heritable genomic modifications. International regulatory bodies and bioethics commissions continue debating permissible boundaries for human gene editing applications, creating policy uncertainty that complicates long-term commercial planning. Restrictive legislative responses in major markets could impose development prohibitions that limit addressable market scope and generate reputational risks for companies associated with contested editing applications.

Covid-19 Impact:

COVID-19 accelerated gene editing technology awareness and investment as CRISPR-based diagnostic assays for rapid viral detection received emergency regulatory authorizations, demonstrating versatility beyond therapeutic applications. Pandemic-era investments in nucleic acid delivery technologies including lipid nanoparticles directly advanced gene editing therapeutic delivery infrastructure. Post-pandemic, increased genomic medicine awareness among payers and clinicians has sustainably expanded reimbursement openness for gene editing therapeutic applications.

The base editing technologies segment is expected to be the largest during the forecast period

The base editing technologies segment is expected to account for the largest market share during the forecast period, due to its ability to introduce precise single-nucleotide changes without creating double-strand DNA breaks, substantially reducing the off-target editing and chromosomal rearrangement risks associated with conventional CRISPR-Cas nuclease systems. This superior safety profile is accelerating regulatory acceptance and clinical adoption for therapeutic applications targeting point mutation-driven genetic diseases. Multiple base editing programs have entered clinical trials, generating a robust late-stage pipeline that is driving segment revenue leadership.

The reagents & consumables segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the reagents & consumables segment is predicted to witness the highest growth rate, driven by expanding research and clinical laboratory adoption of gene editing workflows that generate recurring demand for guide RNA components, Cas protein reagents, delivery vehicle kits, and validation assay consumables. Growing academic and pharmaceutical research activity across gene editing applications is generating compound volume growth in consumable procurement. Standardization of gene editing research protocols across institutions is increasing consumable substitutability, enabling volume purchasing agreements and distribution scale advantages for major reagent suppliers.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, due to leadership in CRISPR therapeutic development, concentration of gene editing biotechnology companies, and robust NIH and private venture funding supporting basic and translational gene editing research. The United States hosts the majority of clinical-stage gene editing programs globally. Established FDA regulatory frameworks for cell and gene therapy products, combined with favorable intellectual property protection infrastructure, sustain North America's dominant position in gene editing commercialization activity.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, due to rapidly expanding genomic research investment in China, South Korea, and Japan, government-backed national gene editing research programs, and growing domestic biotechnology industry capabilities. China has made significant progress in CRISPR research publications and clinical applications, with government funding substantially supporting national genomic innovation strategies. Expanding academic and pharmaceutical research infrastructure across Asia Pacific is generating rising demand for gene editing research tools, reagents, and therapeutic development services.

Key players in the market

Some of the key players in Gene Editing Technologies Market include CRISPR Therapeutics AG, Editas Medicine, Intellia Therapeutics, Sangamo Therapeutics, Caribou Biosciences, Beam Therapeutics, Precision BioSciences, Horizon Discovery Group plc, Lonza Group AG, Thermo Fisher Scientific Inc., Merck KGaA, Agilent Technologies, Inc., Danaher Corporation, GenScript Biotech Corporation, Integrated DNA Technologies (IDT), Takara Bio Inc., New England Biolabs, and Bluebird Bio, Inc..

Key Developments:

In March 2026, GenScript Biotech Corporation expanded its gene editing services platform with new base and prime editing guide RNA design and synthesis capabilities targeting pharmaceutical and academic customers.

In February 2026, Beam Therapeutics reported durable clinical response data from its base editing gene therapy program for sickle cell disease at a major hematology medical conference.

In January 2026, Intellia Therapeutics initiated a Phase III pivotal study of its in vivo CRISPR-based gene editing therapy for hereditary angioedema following positive Phase II efficacy results.

In November 2025, Thermo Fisher Scientific Inc. launched an expanded CRISPR gene editing reagent portfolio including optimized high-fidelity Cas9 variants for reduced off-target genomic modification in therapeutic applications.

Types Covered:

  • CRISPR-Cas Systems
  • TALEN (Transcription Activator-Like Effector Nucleases)
  • Zinc Finger Nucleases (ZFNs)
  • Meganucleases
  • Base Editing Technologies
  • Prime Editing Technologies
  • Other Technology Types

Components Covered:

  • Reagents & Consumables
  • Instruments
  • Software & Bioinformatics Tools
  • Services
  • Kits
  • Enzymes
  • Other Components

Delivery Methods Covered:

  • Viral Vectors
  • Non-viral Vectors
  • Electroporation
  • Microinjection
  • Lipid Nanoparticles
  • Physical Delivery Methods
  • Other Delivery Methods

Applications Covered:

  • Gene Therapy
  • Agricultural Biotechnology
  • Drug Discovery & Development
  • Functional Genomics
  • Cell Line Engineering
  • Diagnostics Development
  • Other Applications

End Users Covered:

  • Biotechnology Companies
  • Pharmaceutical Companies
  • Academic & Research Institutes
  • Contract Research Organizations (CROs)
  • Agricultural Companies
  • Clinical Research Centers
  • Other End Users

Regions Covered:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Spain
    • Netherlands
    • Belgium
    • Sweden
    • Switzerland
    • Poland
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Thailand
    • Malaysia
    • Singapore
    • Vietnam
    • Rest of Asia Pacific
  • South America
    • Brazil
    • Argentina
    • Colombia
    • Chile
    • Peru
    • Rest of South America
  • Rest of the World (RoW)
    • Middle East
  • Saudi Arabia
  • United Arab Emirates
  • Qatar
  • Israel
  • Rest of Middle East
    • Africa
  • South Africa
  • Egypt
  • Morocco
  • Rest of Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 3032 and 2034
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

  • 1.1 Market Snapshot and Key Highlights
  • 1.2 Growth Drivers, Challenges, and Opportunities
  • 1.3 Competitive Landscape Overview
  • 1.4 Strategic Insights and Recommendations

2 Research Framework

  • 2.1 Study Objectives and Scope
  • 2.2 Stakeholder Analysis
  • 2.3 Research Assumptions and Limitations
  • 2.4 Research Methodology
    • 2.4.1 Data Collection (Primary and Secondary)
    • 2.4.2 Data Modeling and Estimation Techniques
    • 2.4.3 Data Validation and Triangulation
    • 2.4.4 Analytical and Forecasting Approach

3 Market Dynamics and Trend Analysis

  • 3.1 Market Definition and Structure
  • 3.2 Key Market Drivers
  • 3.3 Market Restraints and Challenges
  • 3.4 Growth Opportunities and Investment Hotspots
  • 3.5 Industry Threats and Risk Assessment
  • 3.6 Technology and Innovation Landscape
  • 3.7 Emerging and High-Growth Markets
  • 3.8 Regulatory and Policy Environment
  • 3.9 Impact of COVID-19 and Recovery Outlook

4 Competitive and Strategic Assessment

  • 4.1 Porter's Five Forces Analysis
    • 4.1.1 Supplier Bargaining Power
    • 4.1.2 Buyer Bargaining Power
    • 4.1.3 Threat of Substitutes
    • 4.1.4 Threat of New Entrants
    • 4.1.5 Competitive Rivalry
  • 4.2 Market Share Analysis of Key Players
  • 4.3 Product Benchmarking and Performance Comparison

5 Global Gene Editing Technologies Market, By Type

  • 5.1 CRISPR-Cas Systems
  • 5.2 TALEN (Transcription Activator-Like Effector Nucleases)
  • 5.3 Zinc Finger Nucleases (ZFNs)
  • 5.4 Meganucleases
  • 5.5 Base Editing Technologies
  • 5.6 Prime Editing Technologies
  • 5.7 Other Technology Types

6 Global Gene Editing Technologies Market, By Component

  • 6.1 Reagents & Consumables
  • 6.2 Instruments
  • 6.3 Software & Bioinformatics Tools
  • 6.4 Services
  • 6.5 Kits
  • 6.6 Enzymes
  • 6.7 Other Components

7 Global Gene Editing Technologies Market, By Delivery Method

  • 7.1 Viral Vectors
  • 7.2 Non-viral Vectors
  • 7.3 Electroporation
  • 7.4 Microinjection
  • 7.5 Lipid Nanoparticles
  • 7.6 Physical Delivery Methods
  • 7.7 Other Delivery Methods

8 Global Gene Editing Technologies Market, By Application

  • 8.1 Gene Therapy
  • 8.2 Agricultural Biotechnology
  • 8.3 Drug Discovery & Development
  • 8.4 Functional Genomics
  • 8.5 Cell Line Engineering
  • 8.6 Diagnostics Development
  • 8.7 Other Applications

9 Global Gene Editing Technologies Market, By End User

  • 9.1 Biotechnology Companies
  • 9.2 Pharmaceutical Companies
  • 9.3 Academic & Research Institutes
  • 9.4 Contract Research Organizations (CROs)
  • 9.5 Agricultural Companies
  • 9.6 Clinical Research Centers
  • 9.7 Other End Users

10 Global Gene Editing Technologies Market, By Geography

  • 10.1 North America
    • 10.1.1 United States
    • 10.1.2 Canada
    • 10.1.3 Mexico
  • 10.2 Europe
    • 10.2.1 United Kingdom
    • 10.2.2 Germany
    • 10.2.3 France
    • 10.2.4 Italy
    • 10.2.5 Spain
    • 10.2.6 Netherlands
    • 10.2.7 Belgium
    • 10.2.8 Sweden
    • 10.2.9 Switzerland
    • 10.2.10 Poland
    • 10.2.11 Rest of Europe
  • 10.3 Asia Pacific
    • 10.3.1 China
    • 10.3.2 Japan
    • 10.3.3 India
    • 10.3.4 South Korea
    • 10.3.5 Australia
    • 10.3.6 Indonesia
    • 10.3.7 Thailand
    • 10.3.8 Malaysia
    • 10.3.9 Singapore
    • 10.3.10 Vietnam
    • 10.3.11 Rest of Asia Pacific
  • 10.4 South America
    • 10.4.1 Brazil
    • 10.4.2 Argentina
    • 10.4.3 Colombia
    • 10.4.4 Chile
    • 10.4.5 Peru
    • 10.4.6 Rest of South America
  • 10.5 Rest of the World (RoW)
    • 10.5.1 Middle East
      • 10.5.1.1 Saudi Arabia
      • 10.5.1.2 United Arab Emirates
      • 10.5.1.3 Qatar
      • 10.5.1.4 Israel
      • 10.5.1.5 Rest of Middle East
    • 10.5.2 Africa
      • 10.5.2.1 South Africa
      • 10.5.2.2 Egypt
      • 10.5.2.3 Morocco
      • 10.5.2.4 Rest of Africa

11 Strategic Market Intelligence

  • 11.1 Industry Value Network and Supply Chain Assessment
  • 11.2 White-Space and Opportunity Mapping
  • 11.3 Product Evolution and Market Life Cycle Analysis
  • 11.4 Channel, Distributor, and Go-to-Market Assessment

12 Industry Developments and Strategic Initiatives

  • 12.1 Mergers and Acquisitions
  • 12.2 Partnerships, Alliances, and Joint Ventures
  • 12.3 New Product Launches and Certifications
  • 12.4 Capacity Expansion and Investments
  • 12.5 Other Strategic Initiatives

13 Company Profiles

  • 13.1 CRISPR Therapeutics AG
  • 13.2 Editas Medicine
  • 13.3 Intellia Therapeutics
  • 13.4 Sangamo Therapeutics
  • 13.5 Caribou Biosciences
  • 13.6 Beam Therapeutics
  • 13.7 Precision BioSciences
  • 13.8 Horizon Discovery Group plc
  • 13.9 Lonza Group AG
  • 13.10 Thermo Fisher Scientific Inc.
  • 13.11 Merck KGaA
  • 13.12 Agilent Technologies, Inc.
  • 13.13 Danaher Corporation
  • 13.14 GenScript Biotech Corporation
  • 13.15 Integrated DNA Technologies (IDT)
  • 13.16 Takara Bio Inc.
  • 13.17 New England Biolabs
  • 13.18 Bluebird Bio, Inc.

List of Tables

  • Table 1 Global Gene Editing Technologies Market Outlook, By Region (2023-2034)($MN)
  • Table 2 Global Gene Editing Technologies Market Outlook, By Type (2023-2034)($MN)
  • Table 3 Global Gene Editing Technologies Market Outlook, By CRISPR-Cas Systems (2023-2034)($MN)
  • Table 4 Global Gene Editing Technologies Market Outlook, By TALEN (Transcription Activator-Like Effector Nucleases) (2023-2034)($MN)
  • Table 5 Global Gene Editing Technologies Market Outlook, By Zinc Finger Nucleases (ZFNs) (2023-2034)($MN)
  • Table 6 Global Gene Editing Technologies Market Outlook, By Meganucleases (2023-2034)($MN)
  • Table 7 Global Gene Editing Technologies Market Outlook, By Base Editing Technologies (2023-2034)($MN)
  • Table 8 Global Gene Editing Technologies Market Outlook, By Prime Editing Technologies (2023-2034)($MN)
  • Table 9 Global Gene Editing Technologies Market Outlook, By Other Technology Types (2023-2034)($MN)
  • Table 10 Global Gene Editing Technologies Market Outlook, By Component (2023-2034)($MN)
  • Table 11 Global Gene Editing Technologies Market Outlook, By Reagents & Consumables (2023-2034)($MN)
  • Table 12 Global Gene Editing Technologies Market Outlook, By Instruments (2023-2034)($MN)
  • Table 13 Global Gene Editing Technologies Market Outlook, By Software & Bioinformatics Tools (2023-2034)($MN)
  • Table 14 Global Gene Editing Technologies Market Outlook, By Services (2023-2034)($MN)
  • Table 15 Global Gene Editing Technologies Market Outlook, By Kits (2023-2034)($MN)
  • Table 16 Global Gene Editing Technologies Market Outlook, By Enzymes (2023-2034)($MN)
  • Table 17 Global Gene Editing Technologies Market Outlook, By Other Components (2023-2034)($MN)
  • Table 18 Global Gene Editing Technologies Market Outlook, By Delivery Method (2023-2034)($MN)
  • Table 19 Global Gene Editing Technologies Market Outlook, By Viral Vectors (2023-2034)($MN)
  • Table 20 Global Gene Editing Technologies Market Outlook, By Non-viral Vectors (2023-2034)($MN)
  • Table 21 Global Gene Editing Technologies Market Outlook, By Electroporation (2023-2034)($MN)
  • Table 22 Global Gene Editing Technologies Market Outlook, By Microinjection (2023-2034)($MN)
  • Table 23 Global Gene Editing Technologies Market Outlook, By Lipid Nanoparticles (2023-2034)($MN)
  • Table 24 Global Gene Editing Technologies Market Outlook, By Physical Delivery Methods (2023-2034)($MN)
  • Table 25 Global Gene Editing Technologies Market Outlook, By Other Delivery Methods (2023-2034)($MN)
  • Table 26 Global Gene Editing Technologies Market Outlook, By Application (2023-2034)($MN)
  • Table 27 Global Gene Editing Technologies Market Outlook, By Gene Therapy (2023-2034)($MN)
  • Table 28 Global Gene Editing Technologies Market Outlook, By Agricultural Biotechnology (2023-2034)($MN)
  • Table 29 Global Gene Editing Technologies Market Outlook, By Drug Discovery & Development (2023-2034)($MN)
  • Table 30 Global Gene Editing Technologies Market Outlook, By Functional Genomics (2023-2034)($MN)
  • Table 31 Global Gene Editing Technologies Market Outlook, By Cell Line Engineering (2023-2034)($MN)
  • Table 32 Global Gene Editing Technologies Market Outlook, By Diagnostics Development (2023-2034)($MN)
  • Table 33 Global Gene Editing Technologies Market Outlook, By Other Applications (2023-2034)($MN)
  • Table 34 Global Gene Editing Technologies Market Outlook, By End User (2023-2034)($MN)
  • Table 35 Global Gene Editing Technologies Market Outlook, By Biotechnology Companies (2023-2034)($MN)
  • Table 36 Global Gene Editing Technologies Market Outlook, By Pharmaceutical Companies (2023-2034)($MN)
  • Table 37 Global Gene Editing Technologies Market Outlook, By Academic & Research Institutes (2023-2034)($MN)
  • Table 38 Global Gene Editing Technologies Market Outlook, By Contract Research Organizations (CROs) (2023-2034)($MN)
  • Table 39 Global Gene Editing Technologies Market Outlook, By Agricultural Companies (2023-2034)($MN)
  • Table 40 Global Gene Editing Technologies Market Outlook, By Clinical Research Centers (2023-2034)($MN)
  • Table 41 Global Gene Editing Technologies Market Outlook, By Other End Users (2023-2034)($MN)

Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) Regions are also represented in the same manner as above.